Dabur Share Turnaround: Entry Point? (Sep 2026)

Company: Dabur India Ltd · Ghaziabad · Ayurvedic healthcare, hair and oral care, Réal juices; 27% of revenue overseas · NSE and BSE, Nifty 100

Exhibit 1 — Key data

Units: ₹, ₹ crore, percent, times. Consensus and estimates are earnings figures only; AlphaResearch publishes no target price. Nifty FMCG 1M / 3M / 12M changes were not available from a single dated source and are omitted.

Thesis

1. The break was real, self-inflicted in part, and has been repaired to the pre-break rate. Dabur's India volumes fell 7.5% in Q2 FY25 when it halted primary sales for the last week of the quarter to cut distributor inventory, then fell 5.0% in Q4 FY25 on weak urban demand and a delayed winter (Exhibit 5). Four quarters of positive volume growth followed, reaching 6% in Q4 FY26 and 5% in Q1 FY27 — the same rate as Q1 FY25, the last quarter before the break. Revenue is at a record ₹13,552 crore trailing; operating margin is back at 19.7%.
2. The price has not followed, because the market has stopped paying a premium for 5% growth. Dabur traded at 63.5x earnings at its Sep 2024 high and trades at 33.7x now (Exhibit 15); earnings are 7% higher. The whole staples group de-rated with it — HUL is 35% below its 2024 high, Colgate 53%, Godrej Consumer 44% — and within the group the market is now paying roughly in proportion to volume growth: Marico's 11% earns 58.8x, Dabur's and HUL's 5% earn 33–34x (Exhibit 17). At today's price Dabur is not mispriced against its peers; it is priced as one of the slower growers among them.
3. The entry case therefore rests on the next two prints, not on the last three. If volume growth moves from 5% toward 7% while gross margin holds through 8% input inflation, Dabur earns the growth premium back and our bull path (FY28E EPS ₹14.20, 26.4x today) opens. If volume stays at 5% and pricing does the work, the base case (₹12.90, 29.1x) is what ₹375 already pays for. A bear case that stalls volume at 2% leaves the stock at 33.3x FY28E — below its own five-year median but above the Nifty FMCG index — so the asymmetry is present on Dabur's own history and thin against the sector (Exhibit 13).

Our verdict is Neutral at ₹375.00; the reasoning is below.

What the price implies

Dabur pays out about three-quarters of profit, so the dividend-discount identity reads the price cleanly: implied perpetual growth = cost of equity − next year's dividend ÷ price. India's 10-year G-sec yields 7.0% (Ventura, 8 Sep 2026); a 3–5 point equity premium gives a 10–12% cost of equity.

Exhibit 2 — Perpetual dividend growth implied by ₹375.00

Units: percent a year. Source: AlphaResearch arithmetic on the FY26 dividend (Directors' Report), the FY27E dividend (Exhibit 12) and the 10-year yield (Ventura). The delivered record: EPS CAGR 4.2% over FY16–FY26 (₹7.11 → ₹10.68) and 4.5% over FY20–FY26; dividend CAGR 18.4% over FY20–FY26 (₹3.00 → ₹8.25), most of it a payout ratio rising from 37% to 77%, which cannot repeat; consensus EPS CAGR 12.0% for FY26–FY29E (Emkay). The price asks for growth roughly double what the last decade delivered and two-thirds of what the street now forecasts — the middle of the range, which is why the verdict sits in the middle of ours.

Exhibit 3 — The same price read as a multiple

Units: times and ₹ per share. Source: multiples from Exhibit 15 and Ventura; EPS from Screener.in, Exhibit 12 and Emkay. Read one way, the price discounts a permanent one-third cut to Dabur's historical multiple; read the other way, it discounts about one year of consensus growth at the sector multiple and four years at the market's.

AlphaResearch vs consensus

Exhibit 4 — Earnings estimates, AlphaResearch against the street

Units: ₹ per share and ₹ crore. Source: as labelled. Our FY27E is 1% below consensus and FY28E 1.5% below: we take management's double-digit revenue guidance at 10% but hold operating margin to a 20 bps gain a year against the 8% input inflation it flagged, where the street assumes 40–60 bps. Rating distribution (S&P Global via stockanalysis.com, Jun 2026, 37 analysts): 19 Buy, 12 Hold, 6 Sell. Consensus rose through 2026 as the Q3 and Q4 FY26 prints landed; it did not move after Q1 FY27.

Why now — the inflection evidence

The metric that broke was India FMCG volume growth, and the repair began in Q2 FY26.

Exhibit 5 — India volume growth by quarter: the break and the repair

Units: percent and ₹ crore, consolidated. Source: volume from Dabur releases, presentations and transcripts (Q1 FY25 via Moneycontrol; Q2 FY25 via HDFC Securities; Q3 FY25 via ConCallIQ; Q4 FY25 via Motilal Oswal); revenue, net profit and growth from Screener.in; operating margin from Dabur presentations. Q4 is seasonally the weakest quarter for margin. Peak to trough: +5.2% to −7.5%, a 12.7-point swing; trough to latest: +12.5 points; the latest quarter is at the pre-break rate. What is not recovered is the price — 44% below the high — and the multiple, 63.5x then against 33.7x now.

Two qualifications belong here, not in a footnote. First, three of the four repair quarters had help: Q3 and Q4 FY26 were the first full quarters after the GST cuts of 22 Sep 2025 moved hair oils, toothpaste and several health products to a 5% rate, and Q1 FY27 compared against a quarter in which rain had cut glucose sales by 30%. The anniversary of the GST cut falls in Q3 FY27 (results in late Jan 2027), which is when the base normalises. Second, the repair is sector-wide: the Equirus staples review put Q1 FY27 volume growth at 5% for HUL, 7% for Godrej Consumer and Colgate, 9% for Britannia, 11% for Marico and 13% for Tata Consumer. Dabur has recovered with the sector, not ahead of it — the reason the Numbers check below is partial rather than a pass.

Data

The fall in numbers

Exhibit 7 — Reference points to the 8 Sep 2026 close

Units: ₹ and percent. Source: Yahoo Finance daily bars; EPS from Screener.in; AlphaResearch arithmetic. The stock is below its pandemic-panic close with earnings 36% higher, which is another way of saying the multiple has fallen from 48x to 34x while the business grew.

Exhibit 8 — Year-end close, year's high and year's low, 2016–2026

Units: ₹, NSE, intraday highs and lows. Source: Yahoo Finance. Five year-end closes between 2020 and 2025 sat in a ₹500–580 band while EPS moved from ₹8.18 to ₹10.68; 2026 broke the band downward.

Five-year trend and the last five quarters

Exhibit 10 — Consolidated P&L, FY22–FY26 and trailing twelve months

Units: ₹ crore except per-share data and ratios. Source: Screener.in (consolidated); dividends from Stock Price Archive and the Directors' Report. Revenue CAGR FY22–FY26 4.9%, PAT CAGR 1.8%: this is the five-year record the market is now pricing, and the reason a 33.7x multiple is not obviously cheap. ROCE fell seven points as ₹2,700 crore of treasury built up and the Badshah acquisition (FY23) added goodwill.

Estimates

Exhibit 12 — AlphaResearch estimates, FY25–FY28E (consolidated)

Units: ₹ crore, ₹ per share, percent, times. AlphaResearch estimates — inputs to the verdict, not forecasts of price. Source: FY25–FY26 from Screener.in and the Directors' Report; estimates AlphaResearch.

Assumptions

• India FMCG revenue +10% in FY27, +9% in FY28, split roughly half volume (4–5%) and half price, as management guided on the Q1 FY27 call and in the CNBC-TV18 interview; Q1 FY27 delivered 9.5% India FMCG growth on 5% volume (Dabur release).
• International +12% in INR in FY27 after +15.5% in Q1, with MENA (about a fifth of international) flat in constant currency while the war in the region continues (Q1 FY27 presentation).
• Operating margin +20 bps a year to 18.8% and 19.0%: Project Samriddhi cost savings and price hikes offset 8% input inflation with a one-quarter lag; management says margins will be "accretive to top-line growth" (transcript). The street assumes 40–60 bps (Emkay 18.3% → 19.1% FY27E–FY28E on its definition).
• Other income ₹610 crore and ₹640 crore: about 6.5% on a ₹9,500 crore treasury (Screener.in balance sheet).
• Tax 23%, in line with FY24–FY26 (Screener.in); minority interest ₹10 crore.
• Payout 75–76%: the FY26 dividend was 77.2% of consolidated PAT under a policy that has paid 77–80% in FY25–FY26 (Directors' Report).

Bull, base and bear

Exhibit 13 — Three FY28E scenarios at ₹375.00

Units: percent, ₹ per share, times. Source: AlphaResearch estimates — inputs to the verdict, not forecasts of price. Base equals Exhibit 12. The bear case leaves the stock at 33.3x FY28E — below Dabur's own five-year median of 50.8x, so the asymmetry test on its own history passes; it is above the Nifty FMCG index's 31.4x trailing today, so against the sector it does not. Bear EPS of ₹11.25 is above trailing EPS of ₹11.12: the bear case is stagnation, not a collapse, because the balance sheet and payout do not depend on growth.

Valuation

Method: P/E against Dabur's own history and against listed staples peers, with a cash-adjusted cross-check; no sum-of-the-parts, because Dabur reports one consumer business and its international arm is not separately listed or valued by the market.

Exhibit 15 — P/E at six moments, 2021–2026

Units: ₹ and times, trailing fiscal-year EPS at each date. Source: Yahoo Finance closes; Screener.in EPS; AlphaResearch arithmetic. The five fiscal-year-end multiples (FY22–FY26: 54.5x, 56.5x, 50.3x, 50.8x, 38.4x) have a median of 50.8x, the "own five-year median" used throughout; stockanalysis.com's fiscal-year-end series gives the same figures. Today's 33.7x is the lowest of the eight and the lowest since FY17.

Exhibit 17 — Listed staples peers: multiple, yield, volume and drawdown

Units: times and percent. Source: P/E and yield from Motilal Oswal's peer-comparison page (TTM, first week of Sep 2026) except ¹ Dabur, AlphaResearch arithmetic on Screener.in TTM EPS (Bull Run showed 38.8x on 4 Sep on a different EPS basis) and ² Emami, Bull Run (4 Sep 2026) and Screener.in; volume growth from the Equirus 1QFY27 review via Business of Food, Emami like-for-like from its Q1 FY27 release; drawdowns from Yahoo Finance daily highs since 8 Sep 2023, AlphaResearch arithmetic. The pattern is a line, not a scatter: the two companies growing volume at 5% trade at 33–34x, the two at 7% at 41–59x, and the one at 11% at 59x. Emami is the exception in both directions — cheapest multiple, deepest drawdown — and it reported a 15% fall in Q1 FY27 PAT.

Exhibit 19 — What the operating business is priced at, after cash

Units: ₹ crore and times. Source: Screener.in; Prabhudas Lilladher (cash); AlphaResearch arithmetic. Treasury income is about 30% of pre-tax profit (Exhibit 10: other income ₹613 crore of ₹2,513 crore TTM PBT), so the cash-adjusted multiple overstates the operating business's cheapness slightly; the two reads bracket it at 30–34x trailing.

Entry framework

What today's price pays for. At ₹375.00 the stock is 33.7x trailing earnings, 32.1x our FY27E and 29.1x our FY28E (Exhibit 12); its own five-year median is 50.8x and the closest peer on growth, HUL, is 32.8x (Exhibits 15, 17). The bear case leaves it at 33.3x FY28E with a 2.2% yield on a dividend the FY26 payout already covers (Exhibit 13). The price pays for the base case — mid-single-digit volume and pricing that covers inflation — and for nothing beyond it.

How the evidence arrives. The tests come in a fixed order: Q2 FY27 results around 30 Oct 2026 (volume against the 5% run-rate and gross margin against 8% inflation), the Delhi High Court's FSSAI hearing on 16 Dec 2026, Q3 FY27 results in late Jan 2027 (the first quarter without GST-cut help in the base), and Q4 FY27 in May 2027 with the FY27 dividend. A position built across those dates pays more for each confirmation and less for a miss; a single entry today pays today's multiple for all four before any of them has printed. Because Dabur is currently priced level with HUL for the same 5% growth, the evidence favours the staged path: there is no discount today for taking the tests on trust. This piece does not size positions.

Exhibit 20 — Invalidation, in business metrics

Units: percent, ₹ crore, ₹ per share, dates. Source: thresholds AlphaResearch, set against Exhibits 5, 12 and 13. Every level is a printed number in a results release or a court listing; none is a share price.

Who this suits. The catalyst path runs to May 2027 — three results dates and one court date — so the evidence fits a holding horizon measured in quarters, for a reader who can wait for those prints and would treat a 2% volume quarter as a reason to re-read rather than as noise. It does not fit a reader looking for a mispricing against peers today, because on today's numbers there is none (Exhibit 17), nor one who needs the sector's multiple to expand, which is outside anything in this note. Written as description; this piece does not advise.

Who is selling, who is buying

Exhibit 21 — Shareholding pattern, Sep 2023 to Jun 2026

Units: percent of equity. Source: Screener.in. Foreign holders have sold 8.7 points of the company in three years, almost exactly what domestic institutions bought (+8.8 points); the promoter did neither. FII holding at 9.66% is the lowest in the series and about half the Mar 2022 level of 20.43%; the seller is smaller than it was, which is a fact about supply, not a forecast.

Three real entry points

Exhibit 22 — Three real entry points, to 8 Sep 2026

Units: ₹ per share and percent; pre-tax, no reinvestment. Source: prices from Yahoo Finance; dividend ex-dates and amounts from Stock Price Archive, the FY26 final of ₹5.50 from the Directors' Report and AGM. The lesson is the multiple: every buyer of the last six years paid 48x or more and none has been paid for it, the pandemic-low buyer included. Today's 33.7x is the first entry multiple below 40x in that period. That is a fact about the price, not a promise about the next six years, and it is the strongest single argument the entry case has.

Risks

Downside

• Volume growth stays at the bottom of the peer group. Management itself guides to mid-single digits and says price will do half the work while inflation runs at 8%. Every point of volume below our 4–5% is roughly ₹135 crore of revenue and ₹0.14 of FY28E EPS; the bear case (2%) is Exhibit 13.
• Inflation not passed through. Consolidated gross margin was 47.3% in Q1 FY27; crude-linked packaging and oils are the exposure. 100 bps of gross margin not recovered is about ₹145 crore of operating profit and ₹0.63 of EPS against Exhibit 12.
• Rural and the monsoon. Rural outgrew urban for eight quarters and is about half of Dabur's India sales; the company flagged El Niño and uneven rainfall on the Q1 FY27 call. A rural slowdown hits volumes first and beverages hardest.
• The Middle East. International is 27% of revenue; MENA fell 5.4% in constant currency in Q1 FY27 and the region's war has raised input costs in India too. A further 10% constant-currency fall in MENA is about ₹150 crore of revenue.
• Regulatory items. The US FDA warning letter of 24 Jul 2026 found a falsified equipment logbook at the Silvassa plant, placed the site on Import Alert 66-40 (5 Jun 2026) and followed a voluntary recall of US OTC products (2 Jun 2026); the US business is small, but a data-integrity finding is a quality-governance fact, and remediation runs for at least two years of annual audits. The FSSAI order of 3 Aug 2026 against "100%" claims on honey, ghee, oils and coconut water is stayed until the 16 Dec 2026 hearing; a final order would force relabelling across several power brands. The Nov 2023 Mumbai Police FIR naming Mohit and Gaurav Burman in the Mahadev betting-app case has produced no charge in 34 months and RBI and SEBI approved the Burmans as Religare's promoters in Dec 2024, after it — but it is open. Any of the three escalating moves Red flags from partial to fail (Exhibit 20).
• Beverages. Réal lost ground in FY25 to competition and weather; the category grew low single digits in Q1 FY26 and is recovering from a low base. Foods and beverages are 21% of domestic revenue.
• The 5-year record. Revenue CAGR 4.9% and PAT CAGR 1.8% over FY22–FY26 (Exhibit 10). Three good quarters are a start, not a re-based trend; if FY27 ends at high-single-digit rather than double-digit revenue growth, consensus EPS of ₹11.8 is too high and 31.8x becomes 33–34x.

Upside

• Volume catches up with the sector. Godrej Consumer and Colgate printed 7% in Q1 FY27; Dabur at 7% with the same pricing is the bull case: FY28E EPS ₹14.20, 26.4x at today's price (Exhibit 13).
• Margin above our +20 bps a year. Management says FY27 margins will be accretive to revenue growth; the street models 40–60 bps. Each 20 bps above our path is about ₹30 crore of operating profit and ₹0.13 of FY28E EPS.
• Treasury deployed. ₹9,500 crore earning about 6.5% pre-tax; the Sesa Care amalgamation (NCLT order reserved 24 Aug 2026) and further wellness acquisitions would swap treasury yield for operating growth. A ₹2,000 crore acquisition at 15% operating margin adds roughly ₹0.35 of EPS before financing.
• Consensus already sits above us. Our FY27E and FY28E are 1–1.5% below the street (Exhibit 4); if Dabur meets its own double-digit guidance with 40 bps of margin, the street is right and the stock is 28.6x FY28E, not 29.1x.
• The seller is smaller. FII holding has halved since Mar 2022 to 9.66% (Exhibit 21); the domestic bid absorbed it. A pause in foreign selling would remove the supply that has met every rally since Sep 2024.